Veristat names new chief medical officer
Courtesy Business Wire
In a move that Southborough’s Veristat says will strengthen its ongoing offerings expansion, the company has a new chief medical officer.
Jim Roach will begin his role as chief medical officer on Dec. 2, according to a release Monday from the company that specializes in clinical research. In his role, according to a release from the company, Roach will bolster the expansion of its clinical operations, medical and regulatory affairs offerings. He will lead and grow the clinical operations, medical writing, medical monitoring, safety/pharmacovigilance and regulatory affairs teams.
“His experience and leadership will help Veristat partner closely with our clients; providing them with the strategic thinking, executional speed, operational efficiencies and expertise to achieve successful clinical trials and regulatory submission results,” Veristat CEO Patrick Flanagan said in a statement.
Roach has more than 20 years of experience supporting clinical development, registration, commercialization and product lifecycle strategy at several biotechnology, pharmaceutical and clinical research firms. Most recently, according to Veristat, he was senior vice president of development and chief medical officer at Momenta Pharmaceuticals and prior to that was the senior vice president of medical affairs at Sepracor, Inc.
WBJ Web Partners
Most Recent
Most Recent
0 Comments